Brief: Newron Secures Up To 38 Million Euros To Advance Phase III Evenamide Program
16/02/2026 17:11
Feb 16 (Reuters) - Newron Pharmaceuticals SpA NWRN.S: NEWRON SECURES UP TO EUR 38 MILLION TO ADVANCE PHASE III EVENAMIDE PROGRAM NEWRON PHARMACEUTICALS SPA: PROCEEDS EXPECTED TO FUND GLOBAL ENIGMA-TRS STUDIES, EXTEND CASH RUNWAY BEYOND PIVOTAL 12-WEEK RESULTS Source text: ID:nBw230QMBa Further company coverage: NWRN.S ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study